Objective: To determine whether socioeconomic status (SES) influences the likelihood of antibiotic treatment of pulmonary exacerbations in patients with cystic fibrosis (CF). Study design: We used data on 9895 patients ≤18 years old from the Epidemiologic Study of CF. After establishing an individual baseline of clinical signs and symptoms, we ascertained whether antibiotics were prescribed when new signs/symptoms suggested a pulmonary exacerbation, adjusting for sex, presence of Pseudomonas aeruginosa, the number of new signs/symptoms, and baseline disease severity. Results: In a 12-month period, 20.0% of patients <6 years of age, 33.8% of patients 6 to 12 years of age, and 41.4% of patients 13 to 18 years of age were treated with any (oral, intravenous (IV), or inhaled) antibiotics; the percentage receiving IV antibiotics was 7.3%, 15.2%, and 20.9%, respectively. SES had little effect on treatment for pulmonary exacerbation with any antibiotics, but IV antibiotics were prescribed more frequently for patients with lower SES. Conclusions: SES-related disparities in CF health outcomes do not appear to be explained by differential treatment of pulmonary exacerbations.
- Cystic fibrosis
- Epidemiologic Study of Cystic Fibrosis
- Forced expiratory volume in 1 second
- Maternal educational attainment
- Median household income by zip code
- Medicaid or state insurance
- Socioeconomic status